Dr. James Berenson is the Founder, President & Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. Dr. Berenson has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 25 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives. After receiving a Bachelor of Science with Distinction from Stanford University, he earned his Doctorate in Medicine from the University of California at San Diego. Dr. Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. Dr. Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. He has authored and co-authored numerous books, articles, and abstracts in critically renowned journals. Dr. Berenson serves as a member of the National Institutes of Health - Center for Scientific Review, Clinical Oncology Study Section and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He also serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He has received consulting, research funding and honorarium from Celgene, Takeda, Amgen, Janssen and BMS. He has also received research funding and consulting from Incyte.